Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
4594.T Stock Summary
In the News
4594.T Financial details
Company Rating
Neutral
Market Cap
4.65B
Income
-1.21B
Revenue
118K
Book val./share
12.21
Cash/share
20.5
Dividend
-
Dividend %
-
Employees
42
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-4.73
Forward P/E
-
PEG
1.45
P/S
1172.06
P/B
5.73
P/C
3.12
P/FCF
-
Quick Ratio
11.56
Current Ratio
12.1
Debt / Equity
0.65
LT Debt / Equity
-
-
-
EPS (TTM)
-19.26
EPS next Y
-
EPS next Q
-
EPS this Y
-12.78%
EPS next Y
-
EPS next 5Y
-73.52%
EPS last 5Y
-11.14%
Revenue last 5Y
-49.18%
Revenue Q/Q
-17.86%
EPS Q/Q
54.15%
-
-
-
-
SMA20
-14.29%
SMA50
-27.47%
SMA100
-43.1%
Inst Own
-
Inst Trans
-
ROA
-106%
ROE
-87%
ROC
-1.13%
Gross Margin
64%
Oper. Margin
-23568%
Profit Margin
-23884%
Payout
-
Shs Outstand
70.44M
Shs Float
67.55M
-
-
-
-
Target Price
-
52W Range
66.0-185.0
52W High
-65.41%
52W Low
-3.03%
RSI
37
Rel Volume
0.68
Avg Volume
893.34K
Volume
608.8K
Perf Week
-4.48%
Perf Month
-13.51%
Perf Quarter
-53.96%
Perf Half Y
-52.94%
-
-
-
-
Beta
1.347
-
-
Volatility
1.18%, 5.47%
Prev Close
0%
Price
64
Change
-1.54%
4594.T Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 3.72 | 0.27 | 0.05 | 0.3 | 0.09 | |
Net income per share | -44.95 | -44.2 | -36.14 | -28.55 | -24.9 | |
Operating cash flow per share | -34.77 | -42.45 | -37.2 | -29.08 | -20.19 | |
Free cash flow per share | -38.95 | -45.08 | -37.94 | -29.42 | -20.22 | |
Cash per share | 116.93 | 71.81 | 68.63 | 44.33 | 25.66 | |
Book value per share | 121.58 | 76.97 | 74.35 | 48.69 | 26.27 | |
Tangible book value per share | 121.58 | 76.97 | 74.35 | 48.69 | 26.27 | |
Share holders equity per share | 121.58 | 76.97 | 74.35 | 48.69 | 26.27 | |
Interest debt per share | 0 | 0 | 0 | 1.69 | 0 | |
Market cap | 12.66B | 9.12B | 9.28B | 5.36B | 10.26B | |
Enterprise value | 7.76B | 6.1B | 6.01B | 3.14B | 8.73B | |
P/E ratio | -6.72 | -4.91 | -5.4 | -3.61 | -6.91 | |
Price to sales ratio | 81.25 | 807.16 | 3.71K | 347.57 | 1.94K | |
POCF ratio | -8.68 | -5.11 | -5.24 | -3.54 | -8.52 | |
PFCF ratio | -7.75 | -4.81 | -5.14 | -3.5 | -8.51 | |
P/B Ratio | 2.48 | 2.82 | 2.62 | 2.12 | 6.55 | |
PTB ratio | 2.48 | 2.82 | 2.62 | 2.12 | 6.55 | |
EV to sales | 49.79 | 540.05 | 2.4K | 203.65 | 1.65K | |
Enterprise value over EBITDA | -5.62 | -3.53 | -3.56 | -2.17 | -5.99 | |
EV to operating cash flow | -5.32 | -3.42 | -3.4 | -2.08 | -7.25 | |
EV to free cash flow | -4.75 | -3.22 | -3.33 | -2.05 | -7.24 | |
Earnings yield | -0.15 | -0.2 | -0.19 | -0.28 | -0.14 | |
Free cash flow yield | -0.13 | -0.21 | -0.19 | -0.29 | -0.12 | |
Debt to equity | 0 | 0 | 0 | 0.03 | 0 | |
Debt to assets | 0 | 0 | 0 | 0.03 | 0 | |
Net debt to EBITDA | 3.55 | 1.75 | 1.94 | 1.53 | 1.05 | |
Current ratio | 34.68 | 19.25 | 23.34 | 14.6 | 21.57 | |
Interest coverage | 0 | 0 | 0 | -4.08K | -24.05K | |
Income quality | 0.78 | 0.96 | 1.03 | 1.02 | 0.81 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 8.91 | 131.4 | 562.48 | 73.72 | 221.3 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.12 | 0.06 | 0.02 | 0.01 | 0 | |
Capex to revenue | -1.12 | -9.75 | -14.09 | -1.15 | -0.33 | |
Capex to depreciation | -2.12 | -1.76 | -0.53 | -0.5 | -0.11 | |
Stock based compensation to revenue | 0.09 | 0.08 | 0 | 0 | 0 | |
Graham number | 350.67 | 276.67 | 245.88 | 176.84 | 121.33 | |
ROIC | -0.33 | -0.56 | -0.49 | -0.56 | -0.94 | |
Return on tangible assets | -0.36 | -0.53 | -0.46 | -0.54 | -0.87 | |
Graham Net | 111.97 | 66.13 | 64.18 | 39.96 | 23.42 | |
Working capital | 5.01B | 3.16B | 3.49B | 2.51B | 1.57B | |
Tangible asset value | 5.1B | 3.24B | 3.54B | 2.53B | 1.57B | |
Net current asset value | 4.95B | 3.09B | 3.44B | 2.46B | 1.52B | |
Invested capital | 0 | 0 | 0 | 0.03 | 0 | |
Average receivables | 136.22M | 750K | 471K | 8.43M | 8.32M | |
Average payables | 18.55M | 14.57M | 641K | 1.19M | 994.5K | |
Average inventory | 13.78M | 0 | 0 | 0.5 | 0.5 | |
Days sales outstanding | 1.97 | 21.29 | 41.25 | 392.91 | 3.8 | |
Days payables outstanding | 146.27 | 66.51 | 149.19 | 210.39 | 14.83 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 185.27 | 17.15 | 8.85 | 0.93 | 96 | |
Payables turnover | 2.5 | 5.49 | 2.45 | 1.73 | 24.61 | |
Inventory turnover | 0 | 0 | 0 | 3.32M | 0 | |
ROE | -0.37 | -0.57 | -0.49 | -0.59 | -0.95 | |
Capex per share | -4.18 | -2.62 | -0.74 | -0.34 | -0.03 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.08 | 0 | 0 | 0 | 0 | |
Net income per share | -6.73 | -4.14 | -4.7 | -4.1 | -6.32 | |
Operating cash flow per share | 0.14 | 0.13 | 0 | 0 | 0.01 | |
Free cash flow per share | 0.14 | 0.13 | 0 | 0 | 0.01 | |
Cash per share | 28.84 | 24.37 | 20.1 | 16.91 | 20.5 | |
Book value per share | 29.66 | 24.95 | 20.22 | 16.12 | 12.21 | |
Tangible book value per share | 29.64 | 24.95 | 20.22 | 16.12 | 12.21 | |
Share holders equity per share | 29.66 | 24.95 | 20.22 | 16.12 | 12.21 | |
Interest debt per share | 0 | 0 | 0 | 0 | 7.9 | |
Market cap | 6.16B | 10.81B | 8.3B | 8.55B | 5.5B | |
Enterprise value | 4.38B | 9.28B | 7.04B | 7.49B | 4.71B | |
P/E ratio | -3.72 | -10.38 | -7.02 | -8.28 | -3.44 | |
Price to sales ratio | 1.22K | 211.9K | 518.85K | 305.47K | 239.31K | |
POCF ratio | 737.09 | 1.29K | 86.48K | 0 | 10.5K | |
PFCF ratio | 737.09 | 1.29K | 86.48K | 0 | 10.5K | |
P/B Ratio | 3.37 | 6.89 | 6.53 | 8.44 | 7.12 | |
PTB ratio | 3.37 | 6.89 | 6.53 | 8.44 | 7.12 | |
EV to sales | 868.31 | 181.88K | 439.85K | 267.5K | 204.66K | |
Enterprise value over EBITDA | -10.61 | -34.96 | -24.1 | -29.13 | -11.97 | |
EV to operating cash flow | 524.52 | 1.11K | 73.31K | 0 | 8.98K | |
EV to free cash flow | 524.52 | 1.11K | 73.31K | 0 | 8.98K | |
Earnings yield | -0.07 | -0.02 | -0.04 | -0.03 | -0.07 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
Debt to equity | 0 | 0 | 0 | 0 | 0.65 | |
Debt to assets | 0 | 0 | 0 | 0 | 0.35 | |
Net debt to EBITDA | 4.3 | 5.77 | 4.33 | 4.13 | 2.03 | |
Current ratio | 21.18 | 21.57 | 23.28 | 12.1 | 2.31 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | -0.02 | -0.03 | 0 | 0 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 68.35 | 3.52K | 12.05K | 6.11K | 12.33K | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 67.01 | 48.22 | 46.26 | 38.58 | 41.68 | |
ROIC | -0.23 | -0.16 | -0.23 | -0.25 | -0.31 | |
Return on tangible assets | -0.21 | -0.15 | -0.21 | -0.22 | -0.28 | |
Graham Net | 26.51 | 22.24 | 18.26 | 14.52 | 10.13 | |
Working capital | 1.82B | 1.57B | 1.28B | 1.02B | 781.37M | |
Tangible asset value | 1.83B | 1.57B | 1.27B | 1.01B | 772.75M | |
Net current asset value | 1.76B | 1.52B | 1.22B | 963.38M | 723.46M | |
Invested capital | 0 | 0 | 0 | 0 | 0.65 | |
Average receivables | 2.82M | 2.81M | 36.5K | 24K | 27K | |
Average payables | 1.76M | 870K | 40.5K | 8K | 15K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 99 | 97.06 | 101.25 | 96.43 | 93.91 | |
Days payables outstanding | 120.9 | 11.31 | 90 | 154.29 | 324 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0.91 | 0.93 | 0.89 | 0.93 | 0.96 | |
Payables turnover | 0.74 | 7.96 | 1 | 0.58 | 0.28 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.23 | -0.17 | -0.23 | -0.25 | -0.52 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
4594.T Frequently Asked Questions
What is BrightPath Biotherapeutics Co., Ltd. stock symbol ?
BrightPath Biotherapeutics Co., Ltd. is a JP stock and trading under the symbol 4594.T
What is BrightPath Biotherapeutics Co., Ltd. stock quote today ?
BrightPath Biotherapeutics Co., Ltd. stock price is $64 today.
Is BrightPath Biotherapeutics Co., Ltd. stock public?
Yes, BrightPath Biotherapeutics Co., Ltd. is a publicly traded company.